INTRODUCTION
Experimental studies in inbred rats (1) (2) (3) (4) (5) showed that transplacental immunization of the fetus occurred: immunization of a pregnant animal with an insolubilized antigen permanently altered the immune response of its offspring (1, 2) due to the transplacental passage of antigen and its interaction with the developing immune system of the fetus (3), and the effect was ge-netically influenced (2) (3) (4) (5) . In this study we explore this phenomenon in humans. The basic significance of the study would lie in the demonstration that transplacental immunization, which was discovered in a species having a labyrinthine hemotrichorial placenta, occurs in another species, i.e., humans, which has a hemobichorial villous placenta. The clinical significance would lie in the possibility that the technique of transplacental immunization would provide a unique and safe approach to immunization in humans.
Tetanus toxoid (TT)' was chosen as the antigen for this study because it is safe (6) and because there is extensive experience with tetanus immunization in humans (7) (8) (9) (10) (11) (12) (13) (14) (15) . The experimental approach was to immunize females with TT at 5 and 8 mo of pregnancy and to assess the sensitization of their offspring to tetanus and their ability to respond to subsequent immunization with TT compared with the offspring of control (unimmunized) mothers. This stage of pregnancy was chosen for immunization because organogenesis and the major development of the fetus are finished, so any potential teratogenic effect of immunization would be improbable, and it is the most practical time from the clinical point of view. The doses of TT used were those ordinarily employed in immunizing adults (2.5 or 5 Lf) rather than the high doses (30-100 Lf) used in many field studies (9) (10) (11) (12) (13) (14) (15) or recommended for pregnant women exposed to tetanus (6) in order to avoid the possibility of inducing partial immunological tolerance in the offspring (4, 5) . A second question to which this study could contribute is whether pregnant women can respond normally to immunization during pregnancy, which is still a point of some controversy (16) .
METHODS
Study population. The pregnant women were unscreened volunteers from the outpatient clinic at MageeWomen's Hospital. All of them had received three diphtheria, pertussis, tetanus vaccine (DPT) immunizations in childhood, and 12% (8/67) gave a history of one subsequent immunization with TT in childhood or in adolescence. The women entering the study were assigned in alternating sequence to the control (unimmunized) or immunized groups, and all of them were assayed for circulating antitetanus antibody. The immunized women were assigned randomly to receive a standard (5 Lf) or half-standard (2.5 Lf) dose of adult-type TT in order to test any potential effect of the amount of antigen used on the immune response. All of the TT used was from the same batch obtained from the Biological Laboratories, Massachusetts Department of Health. The mothers were vaccinated subcutaneously at 5 and 8 mo of gestation and bled periodically (Fig. 1 ) thereafter for serum antibody and tetanus-induced lymphocyte transformation assays; the control mothers were assayed in parallel. The babies of both the control and the immunized mothers were assayed in the same way. Both groups of babies received the standard three doses of DPT: each dose contained 7.5 Lf diphtheria toxoid. 4 protective units pertussis vaccine, and 5 Lf TT in 0.5 ml. The details of the experimental design are summarized in Fig. 1 . All babies were normal by pediatric evaluation, both at birth and throughout the period of observation (3 yr).
Assay methods. The antibody was measured by a radioimmunoassay that could detect 0.75 ug/ml IgG and 0.4 ,ug/ml IgM (17) . The mixed lymphocyte reaction was performed as described previously (18) . Briefly, heparinized blood from the mothers and babies was used to obtain lym- (20) .
Three types of analyses were done to evaluate the data before using them to answer the experimental questions. First, the effect of the antibody status of the mothers before immunization, i.e., whether they had detectable IgG or IgM antitetanus antibody, was examined to determine its effect on the antibody and lymphocyte transformation responses of their offspring. Second, lymphocyte stimulations were compared in autologous plasma and in AB plasma in order to test for the presence of any immunosuppressive factors in the autologous plasma. Third, the effects of immunizing with a standard or half-standard dose of TT on the antibody and lymphocyte transformation responses of the mothers and the babies were examined.
If none of the variables affected the results, the data were pooled and used to answer two questions. First, are the babies of immunized mothers sensitized to tetanus by transplacental immunization? The criteria for sensitization were: the presence of IgM antitetanus antibody in the cord blood and in the serum before the first DPT immunization; the level of responsiveness to DPT immunization as measured by antibody and lymphocyte transformation assays, and the level of lymphocyte responsiveness 1 yr after birth. Second, can the pregnant female respond to immunization with TT as measured by antibody and lymphocyte transformation responses?
RESULTS
The demographic data for the mothers in the study and for their offspring at birth are summarized in Table I. There were no significant differences among the three groups in the study. Seven women who were tetanus-negative at the beginning of the study were not immunized, and their antibody levels were followed. Six of them subsequently developed measureable amounts of antitetanus antibody, so they had been sensitized to tetanus but their antibody levels at the beginning of the study were undetectable. Similar evidence for tetanus sensitization in women who were ostensibly tetanus-negative when the study began was obtained from lymphocyte transformation studies in autologous plasma and in AB plasma, which showed no differences in the responses to stimulation by TT between mothers who were tetanus negative or tetanus positive when entering the study (Table II) .
To test whether the presence of autologous plasma or of AB plasma influenced the response of lymphocytes to stimulation by TT, assays were performed in parallel in both plasmas and compared by the McNemar test of change: 252 assays were performed with The G-statistic was used for the comparisons between the number of mothers whose lymphocytes were stimulated and those whose lymphocytes were not stimulated. The mothers were further categorized as being either tetatnus negative or tetanus positive at the beginning of the study. lymphocytes from control and immunized mothers; 112 assays, from nonpregnant women, and 212 assays, from babies born to control and immunized mothers.
None showed any differences in lymphocyte stimulation in the two plasmas; therefore, the data were pooled and used as replicate assays. There were no differences in the lymphocyte transformation responses to TT between women immunized with a standard or half-standard dose of TT, using the G-statistic for the comparisons, in 18/19 cases. There were also no differences in the responses of the babies born to mothers immunized with a standard or half-standard dose of TT (Fig. 2) . Finally, there was no significant effect of the dose of TT used for stimulation on the lymphocyte responses of the mothers or of their babies.
The babies of mothers immunized with TT had IgM antitetanus antibodies in their cord blood, whereas the babies of control mothers did not, and the prevalence and the amount of the antibodies were higher in the babies of mothers who received a standard dose of TT (Table III, Fig. 2 ). The tetanus-induced lymphocyte stimulation studies also supported the finding of transplacental immunization of the offspring. The major piece of evidence comes from a comparison of the number of babies from control and immunized mothers whose lymphocytes were stimulated or not stimulated by TT at various times after birth (Table IV) . The babies of immunized mothers responded earlier (by 7 mo of age) to DPT immunization than did the babies of control mothers. More of the babies from immunized mothers had lymphocytes sensitized to TT at 13 mo of age than had sensitized lymphocytes at 7 mo of age (P < 0.01). By contrast, there was no significant difference in the number of babies with sensitized lymphocytes at 7 and 13 mo among the offspring of control mothers. The level of lymphocyte stimulation, or lack thereof, as measured by thymidine incorporation, was the same in the lymphocytes of the babies from control or immunized mothers (Table V) . A comparison of the percentage of babies with stimulated lymphocytes also shows that more of the babies of immunized mothers had sensitized lymphocytes at 7 and 13 mo than did the babies of control mothers (Table V) (Fig. 2) . The immunized mothers responded quite well to immunization with TT (Fig. 3) . The increase in IgG antitetanus antibody production was significant both in the group receiving the standard dose of TT (P < 0.05) and in the group receiving the half-standard dose (P < 0.005), and it exceeded the level of IgG in the control mothers (P < 0.05). The difference in IgM production between the immunized and control groups was not statistically significant, although IgM levels were consistently higher in the immunized mothers. No untoward effects of immunization with TT were observed in the mothers or their offspring. Fig. 3 ). Second, there was a higher lymphocyte transformation response (P < 0.01) to DPT immunization in the babies of immunized mothers (Table V) . Third, the lymphocytes from babies of the immunized mothers were still highly sensitized to TT 13 mo after birth, whereas those from babies of the control (unimmunized) mothers were not (P < 0.01) ( Table V) . These studies in humans reproduce the original experimental observations in rats upon which the protocol was based (1) (2) (3) (4) (5) . They show that active immunization of the pregnant female can sensitize her fetus and that the difference in placental structure in the two species does not affect the transplacental passage of antigen. Studies on pregnant women infected with influenza (21), leprosy (22, 23) , rubella (24, 25) , hepatitis (26, 27) , mumps (28), Escherichia coli (29) or Salmonella typhosa (30) showed that their offspring were sensitized to the microbial antigens, but the possibility of direct infection of the fetus or of placental damage leading to the sensitization cannot be eliminated in this setting. It is highly unlikely that the observations reported here could be due to the transplacental passage of antibodies and sensitized cells from the mother. First, the concentration of IgM antibody is approximately the same in the immunized mothers and in their babies (Figs. 2 and 3) . In order for this to occur by transpla- McNemar test of change was used for the comparisons. The (+) indicates stimulation, and the (-), lack of stimulation. t 0 mo is the cord blood, and 7 mo is 1 mo after the last DPT immunization. Two observations indicate that there is no functional evidence for an immunosuppressive effect during pregnancy. First, the pregnant females responded well to immunization with TT (Fig. 3) ; a similar finding was noted following immunization with influenza vaccine (42, 43 (Tables IV and V) , lasts longer than 1 yr, but the total duration of its protective effect can only be judged by long-term population studies. Transplacental immunization may also be useful with other clinically important vaccines, such as those against the Streptococcus and the Meningococcus, since they are inert polysaccharides which can pass through the placenta (44) . This approach might even be useful with vaccines against diseases that occur in later life, such as gonococcal infection, if the transplacentally induced immunity lasts long enough and if effective vaccines are available.
